A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement

Journal of Korean Medical Science

Volumn 22, Issue 3, 2007, Pages 557-559

  Lee, Soo Youn ^a   Nam, Myung Hyun ^a   June, Soo Kim ^a   Kim, Jong Won ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Cytochrome P 450 CYP2C9; Pharmacogenetics; Polymorphism; Prothrombin time; Warfarin

Indexed keywords

EID: 34447116378     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2007.22.3.557     Document Type: Article

References (20)

1. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
2. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003; 3: 202-14.
3. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603.
4. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
5. Lee JH, Park JS, Chung SW, Sohn DK, Kim SH, Lee HS. Warfarin toxicity patients in the Emergency Department. J Korean Soc Emerg Med 2003; 14: 145-9.
6. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003; 13: 247-52.
7. Higahi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FL, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
8. Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002; 194: 267-73.
9. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-28.
10. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-10.
11. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63.
12. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6: 429-39.
13. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7: 51-8.
14. Ingelman-Sunberg M, Nebert DW, Daly AK. Human cytochrome P450 (CYP) genes. Available from: URL: http://www.imm.ki.se/CYPalleles/cyp2c9.htm (Accession date. 11/25/2005).
15. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 277-80.
16. Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E, Yamane M, Fukumaki Y, Ninomiya H, Tashiro N, Otsubo K, Higuchi S. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000; 10: 85-9.
17. Voora D, McLeod HL, Eby C, Gage BF. Use of pharmacogenetics to guide warfarin therapy. Drugs Today 2004; 40: 247-57.
18. Gage BF, Eby C, Milligan PE, Banet GA, Ducan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94.
19. Lee BK, Lee JY, Jeong YM, Lee MK, Kim KB, Ahn H. Analysis of factors affecting nontherapeutic INRs in Korean outpatients with mechanical heart valves. Korean J Thorac Cardiovasc Surg 2005; 38: 746-60.
20. Lee BK, Lee JY, Jeong YM, Lee MK, Kim KB, Ahn H. Determination of practical dosing of warfarin in Korean outpatients with mechanical heart valves. Korean J Thorac Cardiovasc Surg 2005; 38: 761-72.